Thermo Fisher Scientific Logo
      Video home
      close menu
      Video home
      close
      • Home
      • Antibodies Videos
      • Bioprocessing Videos
      • Cancer Research Videos
      • Cell Culture Videos
      • Cell & Gene Therapy Videos
      • Clinical Microbiology Videos
      • Digital Science Videos
      • DNA & RNA Extraction & Analysis Videos
      • Electron Microscopy
      • Environmental Videos
      • Food and Beverage Videos
      • Genome Editing Videos
      • Manufacturing & Processing Videos
      • Mass Spectrometry Videos
      • PCR Videos
      • Protein Biology Videos
      • Radiation Detection & Measurement Videos
      • Real-Time PCR Videos
      • Sequencing Videos
      • Spectroscopy, Elemental & Isotope Analysis Videos
      • Stem Cell Research

      Early-stage biotech decisions that help drive success

      49:12

      • Share on Facebook
      • Share on X
      • Share on LinkedIn
      • Share via Email
      Description
      Related Videos

      Early-stage biotech companies often face pressure to move quickly from discovery toward clinical development. But decisions made early in a program can have downstream consequences for CMC development, manufacturability, process scale-up, regulatory readiness, and commercialization. In this expert panel discussion, leaders from Thermo Fisher Scientific and biotech organizations share real-world perspectives on the decisions that can shape development strategy and long-term program success. Key topics discussed include: ✓ Why CMC strategy should be considered early in biotech development ✓ Assessing manufacturability and developability risks during discovery ✓Building a target product profile (TPP) early ✓Designing processes and unit operations with scale-up in mind ✓Balancing development speed, quality, and risk ✓Understanding when to build capabilities in-house versus working with external partners ✓ Preparing for effective technology transfer to CDMOs ✓The role of manufacturing, quality, and supply considerations in investor confidence ✓ How platform strategies can support development without replacing molecule-specific CMC planning ✓ How AI, machine learning, and data modeling can support process development and experimental design ✓ Why high-quality, structured data is foundational for effective AI applications ✓ Building CMC capabilities that support programs from discovery through manufacturing The panel emphasizes an important principle for emerging biotech companies: manufacturing and CMC should not be treated as problems to solve later. Early, stage-appropriate planning can help identify and address risks before they become more difficult and expensive to resolve

      View More
      View Less
      Bioprocessing Solutions for Biotech

      Share

      • Share on Facebook
      • Share on X
      • Share on LinkedIn
      • Share via Email

      Related Videos

      In Recently Published Videos

      • Play video Keys to successful lentiviral vector scale-up

        Keys to successful lentiviral vector scale-up

        Lentiviral Vector Scale-Up: Shake Flask to 50 L

        36:24

      • Play video GSK N-1 Perfusion Scale-Up Results at 5 L, 50 L and 500 L

        GSK N-1 Perfusion Scale-Up Results at 5 L, 50 L and 500 L

        See how GSK and Thermo Fisher evaluated N-1 perfusion scale-up in DynaDrive bioreactors, comparing process performance at 5 L, 50 L and 500 L.

        27:09

      • Play video KingFisher Compact technology overview

        KingFisher Compact technology overview

        Thermo Scientific KingFisher Compact is designed to support automated purification for DNA, RNA and Proteins processing 1 to 16 samples per run.

        2:30

      • Play video De-Risking Cell Culture Media Scale-Up for Commercial Manufacturing

        De-Risking Cell Culture Media Scale-Up for Commercial Manufacturing

        Explore strategies to de-risk cell culture media scale-up for commercial manufacturing, including supply assurance, QC readiness, digital tools, and scalable media formats for consistent global production.

        33:40

      • Play video Scalable production of AAV

        Scalable production of AAV

        Scalable production of AAV: demonstrating upstream and downstream approaches

        54:13

      • Play video Mastering AAV production: best practices

        Mastering AAV production: best practices

        Learn AAV-MAX best practices for optimizing AAV production and scaling from small-scale development to manufacturing at up to 1,000 L.

        45:05

      •  
      •  
      •  
      •  
      •  
      Brands
      • Thermo Scientific
      • Applied Biosystems
      • Invitrogen
      • Fisher Scientific
      • Unity Lab Services
      Shopping Tool
      • Product Selection Guides - US
      • Quick Order - US
      • Redeem a Quote
        * Please enter a valid quote
      • New Products
      • Promotions
      • Mobile & Desktop Apps
      • Shared Lists
      eSolutions
      • eProcurement
      • Supply Center
      • Instrument Management
      Support
      • Order Support
      • Training
      • Webinars
      • Blog
      • Social Media
      • Contact Us
      • Report a Site Issue
      Thermo Fisher Scientific
      • About Us
      • Careers
      • Investors
      • News
      • Responsibility
      • Trademarks
      United States
      • Terms & Conditions
      • Privacy Information Center
      • Price & Freight Policy

       

      Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.

      Ok

      Share this video

      Embed

      Size: x pixels